Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series

Table 1 Demographic and clinical characteristics of 22 children with eosinophilic colitis (n = 22)

Characteristic
Age (yr)	9.3 ± 3.2
Gender
Male (n, %)	17 (77.3)
Female (n, %)	5 (22.7)
Weight (kg)	32.0 ± 13.8
WBC count (× 109/L)	11.7 ± 8.9
AEC (/μL)	1692.9 ± 3845.6
Eosinophilia percentage (%)	9.5 ± 14.5
Hemoglobin	126.2 ± 15.2
Albumin (outside the normal range)
Number (%)	3 (13.6)
Value (g/L)	21.9 ± 5.0
CRP (outside the normal range)
Number (%)	15 (68.2)
Value (mg/dL)	11.5 ± 12.1
Total IgE (outside the normal range)
Number (%)	9 (40.9)
Value (kU/L)	520.3 ± 351.2
Allergy history (n, %)
Food allergies	11 (50.0)
Environmental allergies	6 (27.3)
Asthma	3 (13.6)
Eczema	2 (9.1%)
Urticaria	1 (4.5)
Clinical symptoms (n, %)
Abdominal pain	17 (77.3)
Vomiting	9 (40.1)
Diarrhea	3 (13.6)
Nausea	2 (9.1)
HPF
Duodenum	53.1 ± 81.5
Stomach	36.8 ± 50.5
Ileum	49.0 ± 24.0

Continuous variables are expressed as the mean ± SD, while categorical variables are shown as the count and percentage. WBC: White blood cell; AEC: Absolute eosinophil count; CRP: C-reactive protein; IgE: Immunoglobulin E; HPF: High-power field.

Table 2 Case series of 22 children with eosinophilic colitis

Patient	Age/gender	Symptoms	Eosinophil (%)	HB (g/L)	CRP (mg/dL)	Albumin (g/L)	IgE (IU/mL)	HPF			Initial treatment	Relapse	Relapse treatment
								Duodenum	Stomach	Ileum
1	7/male	Vomiting	0.59	111	< 1	44	31	10	40		Lansoprazole	N
2	9/male	Loss of appetite, difficulty swallowing, foreign-body sensation in pharynx	0.76	119	4.3	43.7	58	36	10		Methylprednisolone. Montelukast	N
3	12/male	Abdominal pain	1.00	142	2	43	156	30	4	66	Methylprednisolone	N
4	7/male	Abdominal pain, vomiting	1.02	137	< 1	43	54	25				Y	Montelukast
5	13/male	Abdominal pain, vomiting	1.14	135	32	41.3	624	21	21		Methylprednisolone	N
6	9/male	Abdominal pain, vomiting	1.19	121	< 1	43.1	37	30	28		Methylprednisolone. Montelukast	N
7	3/male	Abdominal pain	1.24	104	24	27	21.9	40	10		Methylprednisolone. Montelukast	N
9	7/female	Abdominal pain, vomiting	1.63	135	21.5	37.6	64	40	10		Lansoprazole. Montelukast	N
10	11/male	Abdominal pain	2.73	141	< 1	47.4	112	26	9		Methylprednisolone. Montelukast	N
11	10/female	Abdominal pain	3.25	132	3.7	41.8	35	8	22		Methylprednisolone	N
12	10/male	Abdominal pain, diarrhea, nausea, burping	4.88	110	6	50	1113	90	5		Montelukast	N
13	11/male	Abdominal pain, vomiting	4.95	132	4.09	41	121	53	8		Methylprednisolone. Montelukast	N
14	13/male	Abdominal pain, vomiting	5.12	151	2.78	46.5	1001	21	6		Lansoprazole. Montelukast	N
15	13/male	Abdominal pain, nausea, acid regurgitation	8.38	121	11.8	37	26	28	4		Montelukast	N
16	11/female	Abdominal pain	9.20	127	39	48	317	60	70		Methylprednisolone. Montelukast	N
17	11/male	Abdominal pain, black stool	10.63	123	< 1	37	155	40	60		Lansoprazole. Montelukast	N
18	14/male	Vomiting, diarrhea	11.83	155	< 1	45	54	30	3	32	Methylprednisolone. Montelukast	N
19	3/male	Periorbital edema, limb swelling	14.66	92	2.25	17	337	30	200		Methylprednisolone. Budesonide	N
20	10/male	Abdominal pain	14.89	122	3.67	41.4	80	48			Methylprednisolone	Y	Methylprednisolone
21	5/male	Periorbital edema, limb swelling	41.63	116	13.7	21.7	649	400	70		Methylprednisolone. Montelukast	Y	Methylprednisolone. Budesonide
22	7/female	Abdominal pain, vomiting, diarrhea	58.50	125	1.88	40.9	331	50	120		Methylprednisolone. Budesonide	N

AEC: Absolute eosinophil count; HB: Hemoglobin; CRP: C-reactive protein; IgE: Immunoglobulin E; HPF: High-power field.